Banco Santander S.A. Lowers Holdings in Edwards Lifesciences Co. (NYSE:EW)

Banco Santander S.A. cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,274 shares of the medical research company’s stock after selling 502 shares during the period. Banco Santander S.A.’s holdings in Edwards Lifesciences were worth $1,602,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at about $29,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Webster Bank N. A. acquired a new position in Edwards Lifesciences during the 2nd quarter valued at approximately $39,000. Finally, Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at $40,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.49 on Friday. The business’s 50 day moving average is $67.70 and its two-hundred day moving average is $75.73. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $41.58 billion, a price-to-earnings ratio of 10.17, a PEG ratio of 3.95 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.59 EPS. Research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on EW shares. Canaccord Genuity Group reduced their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, October 25th. Citigroup decreased their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Finally, Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $75.67.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,000 shares of company stock valued at $2,657,000. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.